CHCosima Hufnagel

Cosima Hufnagel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cosima Hufnagel has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis

    by Frank Friedrich Gellrich, Alaska Kistner, Claudia Guenther, Cosima Hufnagel, Sarah Hobelsberger, Joerg Laske, Stefan Beissert, Daniela Aust, Gustavo Baretton, Nick Reidow, et al.

    Background: The histopathological diagnosis of challenging melanocytic lesions remains limited by substantial interobserver variability. Although computational pathology foundation models demonstrated promising diagnostic performance, their predictions are often difficult to interpret in terms of established criteria. Objective: We evaluated a diagnostic framework combining foundation-model-based whole-slide image analysis, automated prediction of morphological features, and manually assessed PRAME immunohistochemistry. Methods: Using the Virchow2 foundation model and STAMP framework, we analyzed a retrospective cohort of 1,000 melanocytic lesions undergoing PRAME immunohistochemistry. Models were trained on 800 cases and evaluated on a temporally held-out test cohort of 200 cases. Results: The slide-level malignancy classifier achieved a test AUROC of 0.970 (AUPRC 0.984). Separate models predicted established histopathological criteria with high discrimination, including ulceration (AUROC 0.991) and dermal mitoses (AUROC 0.966). In contrast, predicting PRAME expression from H&E images alone showed lower performance (AUROC 0.776-0.780 for PRAME scores 4 and 0). An integrated model combining the slide-level malignancy score, AI-predicted morphological features, and manual PRAME status achieved an AUROC of 0.972 (AUPRC 0.975), comparable to the standalone classifier. In multivariable analysis, PRAME score 4 versus 0 was strongly associated with malignancy (adjusted OR 35.04, 95% CI 17.39-74.62). Conclusions: These findings demonstrate the feasibility of combining foundation-model-based histopathological analysis with established morphological criteria and PRAME immunohistochemistry. Although the integrated framework did not substantially improve overall discrimination, it provides a structured approach for incorporating complementary histopathological and immunohistochemical information into AI-assisted assessment of melanocytic lesions.

  • Open Access

    Correction: 1H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis

    by Frank Friedrich Gellrich, Cosima Hufnagel, Alexander M. Funk, Sophie Jonas, Heidi Altmann, Sarah Hobelsberger, Julian Steininger, Ricarda Rauschenberg, Marlene Garzarolli, Sophia Lehr, et al.

  • Open Access

    ¹H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis

    by Frank Friedrich Gellrich, Cosima Hufnagel, Alexander M Funk, Sophie Jonas, Heidi Altmann, Sarah Hobelsberger, Julian Steininger, Christina Feige, Alpaslan Tasdogan, Triantafyllos Chavakis, et al.

    Early detection of active melanoma metastasis is crucial. Serum metabolomics may offer non-invasive biomarkers, but real-world applicability needs validation. This study aimed to identify ¹H-NMR-based serum metabolic signatures for active metastasis in a large clinical cohort. Serum from 963 melanoma patients (1698 samples) underwent ¹H-NMR spectroscopy. Patients were classified by active metastasis status. OPLS-DA and RFE followed by logistic regression models were developed on a patient-level training/test split. Subgroup analyses assessed signatures related to Immune Checkpoint Inhibitor (ICI) therapy, brain metastases, and BRAF status. Models for active metastasis showed moderate test set discrimination (Area Under the Curve [AUCs]: OPLS-DA 0.609, RFE 0.630). The RFE-model highlighted seven significant metabolites: increased pyruvate, phenylalanine, acetoacetate, glutamate, glucose, and decreased histidine and citrate were associated with active metastasis. OPLS-DA yielded concordant metabolites. Subgroup analyses revealed distinct metabolic associations, e.g., for ICI therapy (citrate, RFE AUC 0.721) and BRAF status (acetate, RFE AUC 0.655), but limited performance for brain metastases (RFE AUC 0.553). ¹H-NMR serum metabolomics detects systemic metabolic alterations of active melanoma metastasis with moderate accuracy in a real-world setting. Identified disruptions in energy and amino acid metabolism offer pathobiological insights and warrant investigation for multimodal biomarker panels.